Medical and biological advances have led to new promising treatments for this cancer that include Radium-223 for bone metastases, pembrolizumab as immunotherapy (PDL1 blocker) for microsatellite instability (MSI) disease, and poly ADP ribose polymerase (PARP) inhibitors for those with mutations in homologous recombination genes, most commonly BRCA2. This evidence concerns the gene CD274 and cancer.